Johnson & Johnson reports strong Q4 and full-year 2024 results, issues positive 2025 guidance

Johnson & Johnson (NYSE:JNJ) today announced its financial results for the fourth quarter and full year ending December 29, 2024, revealing solid growth in both sales and earnings.

Quarterly sales reached $22.5 billion, a 5.3% increase year-over-year, while full-year sales climbed to $88.8 billion, a 4.3% rise from the previous year.

The company reported a fourth-quarter profit of $3.43 billion, with earnings per share (EPS) at $1.41.

Adjusted EPS, impacted by acquisition charges, came in at $2.04.

Key drivers of this performance included strong showings from the Innovative Medicine segment, fueled by products like DARZALEX and ERLEADA.

The MedTech division also contributed significantly to growth, driven by successful new product launches.

Looking forward, Johnson & Johnson provided an optimistic outlook for 2025.

The company anticipates full-year earnings to be in the range of $10.50 to $10.70 per share, with revenue projected between $89.2 billion and $90 billion.